Given the almost ubiquitous occurrence of K-ras mutations and its critical role in the development of pancreatic cancer, the ideal therapeutic strategy would be the direct blocking of KRAS oncogenic signaling. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.